Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients.

Clicks: 385
ID: 80637
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 12 articles by views in journal of neuroimmunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
There is growing evidence for inflammation as a cause and/or consequence of seizures in epilepsy as certain inflammatory biomarkers are elevated. Interleukin (IL)-6, with pro-inflammatory and epileptogenic effects, can perpetuate seizures. Clinical and experimental data support its involvement in acute refractory situations, with some cases responding to treatment with tocilizumab, a humanized monoclonal antibody against the IL-6 receptor. We describe 2 pediatric cases of refractory epilepsy with an abrupt debut responding to tocilizumab. Advances in the knowledge of inflammatory biomarkers involved in epilepsy and the targeted treatment could have important benefits, especially in cases that are refractory to usual treatments.
Reference Key
cantarnextremera2020tocilizumabjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cantarín-Extremera, Verónica;Jiménez-Legido, María;Duat-Rodríguez, Anna;García-Fernández, Marta;Ortiz-Cabrera, Nelmar Valentina;Ruiz-Falcó-Rojas, María Luz;González-Gutiérrez-Solana, Luis;
Journal journal of neuroimmunology
Year 2020
DOI
S0165-5728(19)30492-8
URL
Keywords
epilepsy neuroinflammation tocilizumab interleukin (il)-6 fires/norse reln

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.